Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses

Area of Science:

• Cardiology
• Pathophysiology
• Pharmacology

Background:

• Heart failure traditionally viewed as a hemodynamic syndrome with fluid retention and low cardiac output.
• Progressive cardiac deterioration and dilatation (remodeling) contribute to the fatal nature of heart failure.
• Clinical trials reveal therapies improving hemodynamics may not improve survival, some even worsening prognosis.

Purpose of the Study:

• To re-evaluate the understanding of heart failure beyond a purely hemodynamic syndrome.
• To investigate the role of cardiac remodeling and cellular responses in heart failure prognosis.
• To identify therapeutic targets that address the underlying deterioration and remodeling in heart failure.

Main Methods:

• Analysis of clinical trial data on heart failure therapies.
• Review of pharmacological effects of vasodilators, ACE inhibitors, inotropic agents, beta-blockers, and aldosterone antagonists.
• Examination of the mechanisms underlying cardiac cell death, hypertrophy, and remodeling.

Main Results:

• Most vasodilators improve short-term hemodynamics but shorten survival.
• ACE inhibitors, beta-blockers, and aldosterone antagonists slow cardiac deterioration and remodeling, improving prognosis.
• Inotropic agents provide symptomatic relief but generally reduce long-term survival.

Conclusions:

• Heart failure is a syndrome involving maladaptive proliferative responses leading to cardiac cell death and dilatation.
• Therapeutic strategies must address cardiac remodeling and deterioration, not solely hemodynamic parameters.
• Targeting pathways that inhibit maladaptive hypertrophy, remodeling, and apoptosis is crucial for improving heart failure outcomes.